Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk has tumbled on GLP-1 agonist ... Research from Grand View Research estimates GLP-1 agonist sales in North America could triple from $41 billion last year to $126 billion in 2030 ...

Novo Nordisk is providing direct-to-patient delivery ... Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated in combination with a reduced calorie diet and increased physical ...

Novo Nordisk is introducing a direct-to-patient ... Novo is slashing the cost for all doses of its glucagon-like peptide-receptor agonist (GLP-1RA) to $499 per month, a hefty discount to the ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...